Share On Social!
Latinos face an uphill battle when it comes to their health.
They suffer many inequities, which are worsened amid the COVID-19 pandemic. Beyond that, there is a historical lack of targeted research about these inequities and how to address them, and a lack of diversity in clinical trials.
This is the focus of a new webinar, “Conversations on Cancer: Latino Community—Achieving Equity in Cancer Clinical Trials,” set for 1 p.m. ET Thursday, Sept. 24, 2020. The event is sponsored by the FDA’s Oncology Center of Excellence.
- Amelie G. Ramirez, DrPh, Director of Salud America!, Professor and Chair of the Department of Population Health Sciences, and Director of the Institute for Health Promotion Research, all at UT Health San Antonio
- Pam Balcazar, MS, Cancer Patient Caretaker/Senior Regulatory Project Manager, Office of Oncologic Diseases, FDA
- Marcia Cruz-Correa, MD, PhD, Executive Director/Professor of Medicine & Biochemistry, University of Puerto Rico Comprehensive Cancer
- Ysabel Duron, President/Executive Director, The Latino Cancer Institute
- Jorge Nieva, MD, Associate Professor of Clinical Medicine, University of Southern California
- Georgia Sadler, PhD, Emeritus Professor, Department of Surgery at the University of California San Diego School of Medicine
“The Latino/Hispanic culture, like all cultures, is not monolithic. Even the characterization of people from Latin origins has been classified as Hispanic, Latino, and more recently, Latinx,” according to the FDA. “We hope to honor the diaspora and delve into some of the nuances of the Latino culture as it relates to enrollment on cancer clinical trials.”
Learn more about COVID-19 and Latino health equity: